$10.41
2.07% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US00650F1093
Symbol
ADPT

Adaptive Biotechnologies Corp Stock price

$10.41
+0.90 9.46% 1M
+4.25 68.99% 6M
+4.42 73.64% YTD
+6.95 200.87% 1Y
-32.30 75.63% 5Y
-9.59 47.95% 10Y
-9.59 47.95% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
-0.22 2.07%
ISIN
US00650F1093
Symbol
ADPT
Sector
Industry

Key metrics

Market capitalization $1.58b
Enterprise Value $1.52b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.03
P/S ratio (TTM) P/S ratio 8.34
P/B ratio (TTM) P/B ratio 8.30
Revenue growth (TTM) Revenue growth 8.61%
Revenue (TTM) Revenue $189.53m
EBIT (operating result TTM) EBIT $-143.39m
Free Cash Flow (TTM) Free Cash Flow $-88.76m
Cash position $193.42m
EPS (TTM) EPS $-0.96
P/E forward negative
P/S forward 7.24
EV/Sales forward 6.97
Short interest 8.13%
Show more

Is Adaptive Biotechnologies Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Adaptive Biotechnologies Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Adaptive Biotechnologies Corp forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Adaptive Biotechnologies Corp forecast:

Buy
86%
Hold
14%

Financial data from Adaptive Biotechnologies Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
190 190
9% 9%
100%
- Direct Costs 71 71
5% 5%
37%
119 119
19% 19%
63%
- Selling and Administrative Expenses 156 156
9% 9%
82%
- Research and Development Expense 88 88
19% 19%
46%
-133 -133
36% 36%
-70%
- Depreciation and Amortization 11 11
16% 16%
6%
EBIT (Operating Income) EBIT -143 -143
34% 34%
-76%
Net Profit -142 -142
34% 34%
-75%

In millions USD.

Don't miss a Thing! We will send you all news about Adaptive Biotechnologies Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adaptive Biotechnologies Corp Stock News

Neutral
GlobeNewsWire
14 days ago
SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be inclu...
Neutral
GlobeNewsWire
16 days ago
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL.
Neutral
Seeking Alpha
about one month ago
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of Investor Relations & FP&A Chad Robins - Chief Executive Officer & Co-Founder Kyle Piskel - Chief Financial Officer Susan Bobulsky - Chief Commercial Officer Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandler Y...
More Adaptive Biotechnologies Corp News

Company Profile

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Head office United States
CEO Chad Robins
Employees 619
Founded 2009
Website www.adaptivebiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today